XIST : A Meaningful Long Noncoding RNA in NSCLC Process
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
BACKGROUND: A number of studies have proposed that lncRNA XIST plays a role in the development and chemosensitivity of NSCLC. Besides, XIST may become a potential therapeutic target for NSCLC patients. The aim of this review is to reveal the biological functions and exact mechanisms of XIST in NSCLC.
METHODS: In this review, relevant researches involving the relationship between XIST and NSCLC are collected through systematic retrieval of PubMed.
RESULTS: XIST is an oncogene in NSCLC and is abnormally upregulated in NSCLC tissues. Considerable evidence has shown that XIST plays a critical role in the proliferation, invasion, migration, apoptosis and chemosensitivity of NSCLC cells. XIST mainly functions as a ceRNA in the NSCLC process, while XIST also functions at transcriptional levels.
CONCLUSION: LncRNA XIST has the potential to become a novel biomolecular marker of NSCLC and a therapeutic target for NSCLC.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:27 |
|---|---|
| Enthalten in: |
Current pharmaceutical design - 27(2021), 11 vom: 03., Seite 1407-1417 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Shen, Yujie [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Biomolecular marker |
|---|
| Anmerkungen: |
Date Completed 30.06.2021 Date Revised 31.05.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.2174/1381612826999201202102413 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM318339382 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM318339382 | ||
| 003 | DE-627 | ||
| 005 | 20231225165141.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/1381612826999201202102413 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1061.xml |
| 035 | |a (DE-627)NLM318339382 | ||
| 035 | |a (NLM)33267757 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Shen, Yujie |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a XIST |b A Meaningful Long Noncoding RNA in NSCLC Process |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 30.06.2021 | ||
| 500 | |a Date Revised 31.05.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
| 520 | |a BACKGROUND: A number of studies have proposed that lncRNA XIST plays a role in the development and chemosensitivity of NSCLC. Besides, XIST may become a potential therapeutic target for NSCLC patients. The aim of this review is to reveal the biological functions and exact mechanisms of XIST in NSCLC | ||
| 520 | |a METHODS: In this review, relevant researches involving the relationship between XIST and NSCLC are collected through systematic retrieval of PubMed | ||
| 520 | |a RESULTS: XIST is an oncogene in NSCLC and is abnormally upregulated in NSCLC tissues. Considerable evidence has shown that XIST plays a critical role in the proliferation, invasion, migration, apoptosis and chemosensitivity of NSCLC cells. XIST mainly functions as a ceRNA in the NSCLC process, while XIST also functions at transcriptional levels | ||
| 520 | |a CONCLUSION: LncRNA XIST has the potential to become a novel biomolecular marker of NSCLC and a therapeutic target for NSCLC | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a NSCLC | |
| 650 | 4 | |a RNA | |
| 650 | 4 | |a XIST | |
| 650 | 4 | |a biomolecular marker | |
| 650 | 4 | |a noncoding | |
| 650 | 4 | |a therapeutic target | |
| 650 | 7 | |a MicroRNAs |2 NLM | |
| 650 | 7 | |a RNA, Long Noncoding |2 NLM | |
| 650 | 7 | |a XIST non-coding RNA |2 NLM | |
| 700 | 1 | |a Lin, Yexiang |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Kai |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Jinlan |e verfasserin |4 aut | |
| 700 | 1 | |a Zhong, Juanjuan |e verfasserin |4 aut | |
| 700 | 1 | |a Gao, Yisong |e verfasserin |4 aut | |
| 700 | 1 | |a Yuan, Chengfu |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current pharmaceutical design |d 1998 |g 27(2021), 11 vom: 03., Seite 1407-1417 |w (DE-627)NLM095430172 |x 1873-4286 |7 nnns |
| 773 | 1 | 8 | |g volume:27 |g year:2021 |g number:11 |g day:03 |g pages:1407-1417 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2174/1381612826999201202102413 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 27 |j 2021 |e 11 |b 03 |h 1407-1417 | ||